Difference between revisions of "SPECT Biomarker Ctte"

From QIBA Wiki
Jump to navigation Jump to search
Line 18: Line 18:
 
* Clinical / Literature Review – ''Dr. Seibyl''
 
* Clinical / Literature Review – ''Dr. Seibyl''
  
==Meetings/Call Summaries==
+
==Recent Meetings/Call Summaries==
 
*[[SPECT Call Summaries]]
 
*[[SPECT Call Summaries]]
 +
 +
[[SPECT BC Call Summaries Archive]]
  
 
==Literature Review (Profile 1.0)==
 
==Literature Review (Profile 1.0)==

Revision as of 17:49, 10 November 2017

Co-chairs: Yuni Dewaraja, PhD; P. David Mozley, MD; John Seibyl, MD
Secretary: Julie Lisiecki

Project Snapshot

The SPECT Biomarker Committee seeks to develop a quantitative imaging profile for SPECT imaging.

Under consideration:

  • quantifying a small structure (like the basal ganglion in the DaTscan, thyroid)
  • quantifying organs, like the liver, for dosimetry as potential use cases

Established Task Forces currently working toward a first Profile titled: Quantifying Dopamine Transporters with 123-Iodine labeled Ioflupane in Neurodegenerative Disease

  • Image Acquisition and Image Processing for DaTscan – Dr. Dewaraja
  • Quantitative / Image Analysis – Drs. Miyaoka and Seibyl
  • Phantoms / DRO Group – Drs. Dickson and Zimmerman
  • Clinical / Literature Review – Dr. Seibyl

Recent Meetings/Call Summaries

SPECT BC Call Summaries Archive

Literature Review (Profile 1.0)

Profile Development

Reference Materials